secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2024-04-19T23:59:59+00:00
Accession:  0001567264-24-000003
Event type: regulatory
Sentiment:  negative
Materiality: 0.55
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics receives Nasdaq non-compliance notice after director resigns from audit committee
--------------------------------------------------------------------------------

- Daniel Donovan resigned from audit committee on April 12, 2024, leaving only 2 members; company received Nasdaq deficiency letter on April 18, 2024.
- Cure period runs until earlier of next annual stockholder meeting or April 14, 2025; if annual meeting before Oct 9, 2024, then cure expires Oct 9, 2024.
- Company intends to appoint a new independent director to the board to serve on the audit committee within the cure period.
- Failure to regain compliance could result in delisting; company may appeal any delisting determination to a hearings panel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000156726424000003/0001567264-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000156726424000003/intensity-20240418.htm
  HTML page:      https://secwatch.observer/filing/0001567264-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer